Delaware | 1-14064 | 11-2408943 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
767 Fifth Avenue, New York, New York | 10153 | |||||||||||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Class A Common Stock, $.01 par value | EL | New York Stock Exchange |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Exhibit No. | Description | ||||||||||
99.1 | |||||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
THE ESTÉE LAUDER COMPANIES INC. | |||||||||||
Date: | February 2, 2023 | By: | /s/ Tracey T. Travis | ||||||||
Tracey T. Travis | |||||||||||
Executive Vice President and Chief Financial Officer | |||||||||||
(Principal Financial and Accounting Officer) |
767 Fifth Avenue New York, NY 10153 | News Contact: Investors: Rainey Mancini rmancini@estee.com Media: Jill Marvin jimarvin@estee.com |
Page 1 of 22 |
Reconciliation between GAAP and Non-GAAP Net Sales Growth (Unaudited) | |||||
Three Months Ended December 31, 2022(3) | |||||
As Reported - GAAP(1) | (17) | % | |||
Organic, Non-GAAP(2) | (11) | % | |||
Impact of the license terminations related to certain of the Company’s designer fragrances | (1) | ||||
Impact of foreign currency translation | (5) | ||||
Returns associated with restructuring and other activities | — | ||||
As Reported - GAAP(1) | (17) | % | |||
(1)Includes returns associated with restructuring and other activities | |||||
(2)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (the license terminations related to certain of the Company’s designer fragrances); as well as the impact of foreign currency translation. | |||||
(3)Percentages are calculated on an individual basis |
Page 2 of 22 |
Page 3 of 22 |
Results by Product Category (Unaudited) | |||||||||||||||||||||||
Three Months Ended December 31 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income (Loss) | Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
Skin Care | $ | 2,382 | $ | 3,159 | (25) | % | (20) | % | $ | 421 | $ | 1,082 | (61) | % | |||||||||
Makeup | 1,268 | 1,386 | (9) | (3) | (37) | 130 | (100+) | ||||||||||||||||
Fragrance | 775 | 799 | (3) | 3 | 177 | 210 | (16) | ||||||||||||||||
Hair Care | 182 | 180 | 1 | 4 | 5 | 8 | (38) | ||||||||||||||||
Other | 14 | 16 | (13) | — | (1) | 3 | (100+) | ||||||||||||||||
Subtotal | $ | 4,621 | $ | 5,540 | (17) | % | (11) | % | $ | 565 | $ | 1,433 | (61) | % | |||||||||
Returns/charges associated with restructuring and other activities | (1) | (1) | (9) | (15) | |||||||||||||||||||
Total | $ | 4,620 | $ | 5,539 | (17) | % | (12) | % | $ | 556 | $ | 1,418 | (61) | % |
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Three Months Ended December 31 2022 vs. 2021(2) | ||||||||||||||
Organic Net Sales Growth (Non-GAAP)(1) | Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) | |||||||||||
Skin Care | (20) | % | — | % | (5) | % | (25) | % | ||||||
Makeup | (3) | — | (5) | (9) | ||||||||||
Fragrance | 12 | (9) | (6) | (3) | ||||||||||
Hair Care | 4 | — | (3) | 1 | ||||||||||
Other | (6) | 6 | (13) | (13) | ||||||||||
Subtotal | (11) | % | (1) | % | (5) | % | (17) | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | (11) | % | (1) | % | (5) | % | (17) | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (the license terminations related to certain of the Company’s designer fragrances); as well as the impact of foreign currency translation. | ||||||||||||||
(2)Percentages are calculated on an individual basis |
Page 4 of 22 |
Page 5 of 22 |
Results by Geographic Region (Unaudited) | |||||||||||||||||||||||
Three Months Ended December 31 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income (Loss) | Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
The Americas | $ | 1,235 | $ | 1,300 | (5) | % | (6) | % | $ | (85) | $ | 382 | (100+)% | ||||||||||
Europe, the Middle East & Africa | 1,816 | 2,338 | (22) | (18) | 409 | 620 | (34) | ||||||||||||||||
Asia/Pacific | 1,570 | 1,902 | (17) | (8) | 241 | 431 | (44) | ||||||||||||||||
Subtotal | $ | 4,621 | $ | 5,540 | (17) | % | (11) | % | $ | 565 | $ | 1,433 | (61) | % | |||||||||
Returns/charges associated with restructuring and other activities | (1) | (1) | (9) | (15) | |||||||||||||||||||
Total | $ | 4,620 | $ | 5,539 | (17) | % | (12) | % | $ | 556 | $ | 1,418 | (61) | % |
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Three Months Ended December 31 2022 vs. 2021(2) | ||||||||||||||
Organic Net Sales Growth (Non-GAAP)(1) | Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) | |||||||||||
The Americas | (3) | % | (2) | % | 1 | % | (5) | % | ||||||
Europe, the Middle East & Africa | (17) | (1) | (4) | (22) | ||||||||||
Asia/Pacific | (7) | — | (10) | (17) | ||||||||||
Subtotal | (11) | % | (1) | % | (5) | % | (17) | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | (11) | % | (1) | % | (5) | % | (17) | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (the license terminations related to certain of the Company’s designer fragrances); as well as the impact of foreign currency translation. | ||||||||||||||
(2)Percentages are calculated on an individual basis |
Page 6 of 22 |
Page 7 of 22 |
Page 8 of 22 |
Page 9 of 22 |
Page 10 of 22 |
Page 11 of 22 |
Page 12 of 22 |
Page 13 of 22 |
CONSOLIDATED STATEMENT OF EARNINGS (Unaudited) | |||||||||||||||||||||||
Three Months Ended December 31 | Percentage Change | Six Months Ended December 31 | Percentage Change | ||||||||||||||||||||
($ in millions, except per share data) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net sales(A) | $ | 4,620 | $ | 5,539 | (17) | % | $ | 8,550 | $ | 9,931 | (14) | % | |||||||||||
Cost of sales(A) | 1,219 | 1,223 | — | 2,242 | 2,280 | (2) | |||||||||||||||||
Gross profit | 3,401 | 4,316 | (21) | 6,308 | 7,651 | (18) | |||||||||||||||||
Gross margin | 73.6 | % | 77.9 | % | 73.8 | % | 77.0 | % | |||||||||||||||
Operating expenses | |||||||||||||||||||||||
Selling, general and administrative(B) | 2,630 | 2,885 | (9) | 4,874 | 5,279 | (8) | |||||||||||||||||
Restructuring and other charges(A) | 8 | 13 | (38) | 10 | 19 | (47) | |||||||||||||||||
Impairment of other intangible assets(C) | 207 | — | 100 | 207 | — | 100 | |||||||||||||||||
Total operating expenses | 2,845 | 2,898 | (2) | 5,091 | 5,298 | (4) | |||||||||||||||||
Operating expense margin | 61.6 | % | 52.3 | % | 59.5 | % | 53.3 | % | |||||||||||||||
Operating income | 556 | 1,418 | (61) | 1,217 | 2,353 | (48) | |||||||||||||||||
Operating income margin | 12.0 | % | 25.6 | % | 14.2 | % | 23.7 | % | |||||||||||||||
Interest expense | 52 | 42 | 24 | 98 | 84 | 17 | |||||||||||||||||
Interest income and investment income, net | 26 | 10 | 100+ | 41 | 14 | 100+ | |||||||||||||||||
Other components of net periodic benefit cost | (2) | (2) | — | (5) | (1) | (100+) | |||||||||||||||||
Other income | — | — | — | — | 1 | (100) | |||||||||||||||||
Earnings before income taxes | 532 | 1,388 | (62) | 1,165 | 2,285 | (49) | |||||||||||||||||
Provision for income taxes | 135 | 298 | (55) | 278 | 500 | (44) | |||||||||||||||||
Net earnings | 397 | 1,090 | (64) | 887 | 1,785 | (50) | |||||||||||||||||
Net earnings attributable to noncontrolling interests | — | (4) | 100 | — | (5) | 100 | |||||||||||||||||
Net loss (earnings) attributable to redeemable noncontrolling interest | (3) | 2 | (100+) | (4) | — | (100) | |||||||||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. | $ | 394 | $ | 1,088 | (64) | % | $ | 883 | $ | 1,780 | (50) | % | |||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. per common share | |||||||||||||||||||||||
Basic | $ | 1.10 | $ | 3.02 | (64) | % | $ | 2.47 | $ | 4.93 | (50) | % | |||||||||||
Diluted | $ | 1.09 | $ | 2.97 | (63) | % | $ | 2.45 | $ | 4.85 | (50) | % | |||||||||||
Weighted-average common shares outstanding | |||||||||||||||||||||||
Basic | 357.7 | 360.6 | 357.8 | 361.4 | |||||||||||||||||||
Diluted | 360.4 | 366.0 | 360.9 | 367.0 | |||||||||||||||||||
(A)In August 2020, the Company announced a two-year restructuring program, Post-COVID Business Acceleration Program (the “PCBA Program”), designed to realign its business to address the dramatic shifts to its distribution landscape and consumer behaviors in the wake of the COVID-19 pandemic. The PCBA Program will help improve efficiency and effectiveness by rebalancing resources to growth areas of prestige beauty. It is expected to further strengthen the Company by building upon the foundational capabilities in which the Company has invested. The PCBA Program’s main areas of focus include accelerating the shift to online with the realignment of the Company’s distribution network reflecting freestanding store and certain department store closures, with a focus on North America and Europe, the Middle East & Africa; the reduction in brick-and-mortar point of sale employees and related support staff; and the redesign of the Company’s regional branded marketing organizations, plus select opportunities in global brands and functions. This program is expected to position the Company to better execute its long-term strategy while strengthening its financial flexibility. The Company approved specific initiatives under the PCBA Program through fiscal 2022 and expects to substantially complete those initiatives through fiscal 2023. The Company expects that the PCBA Program will result in related restructuring and other charges totaling between $500 million and $515 million, before taxes. |
Page 14 of 22 |
(B)For the three and six months ended December 31, 2022, the Company recorded $(4) million ($(4) million, less the portion attributable to redeemable noncontrolling interest and net of tax) and $(3) million ($(3) million, less the portion attributable to redeemable noncontrolling interest and net of tax), respectively, of income related to the change in fair value of acquisition-related stock options related to DECIEM, and recorded $2 million ($2 million, less the portion attributable to redeemable noncontrolling interest and net of tax) for the three and six months ended December 31, 2021. | |||||||||||||||||||||||
(C)During the fiscal 2023 second quarter, given the lower-than-expected results in the overall business, the Company made revisions to the internal forecasts relating to its Smashbox reporting unit. The Company concluded that the changes in circumstances in the reporting unit triggered the need for an interim impairment review of its trademark intangible asset. The remaining carrying value of the trademark intangible asset was not recoverable and the Company recorded an impairment charge of $21 million reducing the carrying value to zero. During the fiscal 2023 second quarter, the Dr.Jart+ reporting unit experienced lower-than-expected growth within key geographic regions and channels that continue to be impacted by the spread of COVID-19 variants, resurgence in cases, and the potential future impacts relating to the uncertainty of the duration and severity of COVID-19 impacting the financial performance of the reporting unit. In addition, due to macro-economic factors, Dr.Jart+ has experienced lower-than-expected growth within key geographic regions. The Too Faced reporting unit experienced lower-than-expected results in key geographic regions and channels coupled with delays in future international expansion to areas that continue to be impacted by COVID-19. As a result, the Company made revisions to the internal forecasts relating to its Dr.Jart+ and Too Faced reporting units. Additionally, there were increases in the weighted average cost of capital for both reporting units as compared to the prior year annual goodwill and other indefinite-lived intangible asset impairment testing as of April 1, 2022. The Company concluded that the changes in circumstances in the reporting units, along with increases in the weighted average cost of capital, triggered the need for interim impairment reviews of their trademarks and goodwill. These changes in circumstances were also an indicator that the carrying amounts of Dr.Jart+’s and Too Faced’s long-lived assets, including customer lists, may not be recoverable. Accordingly, the Company performed interim impairment tests for the trademarks and a recoverability test for the long-lived assets as of November 30, 2022. The Company concluded that the carrying value of the trademark intangible assets exceeded their estimated fair values, which were determined utilizing the relief-from-royalty method to determine discounted projected future cash flows and recorded an impairment charge of $100 million for Dr.Jart+ and $86 million for Too Faced. The Company concluded that the carrying amounts of the long-lived assets were recoverable. After adjusting the carrying values of the trademarks, the Company completed interim quantitative impairment tests for goodwill. As the estimated fair value of the Dr.Jart+ and Too Faced reporting units were in excess of their carrying values, the Company concluded that the carrying amounts of the goodwill were recoverable and did not record a goodwill impairment charge related to these reporting units. The fair values of these reporting units were based upon an equal weighting of the income and market approaches, utilizing estimated cash flows and a terminal value, discounted at a rate of return that reflects the relative risk of the cash flows, as well as valuation multiples derived from comparable publicly traded companies that are applied to operating performance of the reporting units. The significant assumptions used in these approaches include revenue growth rates and profit margins, terminal values, weighted average cost of capital used to discount future cash flows and royalty rates for trademarks. The most significant unobservable input used to estimate the fair values of the Dr.Jart+ and Too Faced trademark intangible assets was the weighted-average cost of capital, which was 11% and 13%, respectively. For the three and six months ended December 31, 2022, other intangible asset impairment charges were $207 million ($159 million, net of tax), with an impact of $.44 per common share in both periods. | |||||||||||||||||||||||
Page 15 of 22 |
Returns and Charges Associated With Restructuring and Other Activities and Other Adjustments (Unaudited) | |||||||||||||||||||||||
Three Months Ended December 31, 2022 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges | Other Charges/ Adjustments | |||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | — | $ | — | $ | 1 | $ | 1 | $ | 1 | $ | — | |||||||||
PCBA Program | 1 | — | 4 | 3 | 8 | 6 | .02 | ||||||||||||||||
Change in fair value of acquisition-related stock options | — | — | — | (4) | (4) | (4) | (.01) | ||||||||||||||||
Other intangible asset impairments | — | — | — | 207 | 207 | 159 | .44 | ||||||||||||||||
Total | $ | 1 | $ | — | $ | 4 | $ | 207 | $ | 212 | $ | 162 | $ | .45 | |||||||||
Six Months Ended December 31, 2022 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges | Other Charges/ Adjustments | |||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | — | $ | (2) | $ | 3 | $ | 1 | $ | 1 | $ | — | |||||||||
PCBA Program | 6 | (1) | 6 | 3 | 14 | 10 | .03 | ||||||||||||||||
Change in fair value of acquisition-related stock options | — | — | — | (3) | (3) | (3) | (.01) | ||||||||||||||||
Other intangible asset impairments | — | — | — | 207 | 207 | 159 | .44 | ||||||||||||||||
Total | $ | 6 | $ | (1) | $ | 4 | $ | 210 | $ | 219 | $ | 167 | $ | .46 | |||||||||
Three Months Ended December 31, 2021 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges | Other Charges/ Adjustments | |||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | 2 | $ | (2) | $ | 5 | $ | 5 | $ | 4 | $ | .01 | |||||||||
PCBA Program | 1 | (1) | 7 | 3 | 10 | 8 | .02 | ||||||||||||||||
Change in fair value of acquisition-related stock options | — | — | — | 2 | 2 | 2 | .01 | ||||||||||||||||
Total | $ | 1 | $ | 1 | $ | 5 | $ | 10 | $ | 17 | $ | 14 | $ | .04 | |||||||||
Six Months Ended December 31, 2021 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges | Other Charges/ Adjustments | |||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | 2 | $ | (1) | $ | 8 | $ | 9 | $ | 7 | $ | .02 | |||||||||
PCBA Program | 2 | (2) | 7 | 5 | 12 | 10 | .03 | ||||||||||||||||
Change in fair value of acquisition-related stock options | — | — | — | 2 | 2 | 2 | — | ||||||||||||||||
Other income | — | — | — | (1) | (1) | (1) | — | ||||||||||||||||
Total | $ | 2 | $ | — | $ | 6 | $ | 14 | $ | 22 | $ | 18 | $ | .05 |
Page 16 of 22 |
Results by Product Category (Unaudited) | |||||||||||||||||||||||
Six Months Ended December 31 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income (Loss) | Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
Skin Care | $ | 4,486 | $ | 5,608 | (20) | % | (16) | % | $ | 951 | $ | 1,799 | (47) | % | |||||||||
Makeup | 2,320 | 2,560 | (9) | (5) | (21) | 221 | (100+) | ||||||||||||||||
Fragrance | 1,382 | 1,408 | (2) | 4 | 310 | 341 | (9) | ||||||||||||||||
Hair Care | 340 | 328 | 4 | 7 | (7) | 10 | (100+) | ||||||||||||||||
Other | 28 | 29 | (3) | 3 | (1) | 3 | (100+) | ||||||||||||||||
Subtotal | $ | 8,556 | $ | 9,933 | (14) | % | (9) | % | $ | 1,232 | $ | 2,374 | (48) | % | |||||||||
Returns/charges associated with restructuring and other activities | (6) | (2) | (15) | (21) | |||||||||||||||||||
Total | $ | 8,550 | $ | 9,931 | (14) | % | (9) | % | $ | 1,217 | $ | 2,353 | (48) | % |
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Six Months Ended December 31 2022 vs. 2021(2) | ||||||||||||||
Organic Net Sales Growth (Non-GAAP)(1) | Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) | |||||||||||
Skin Care | (16) | % | — | % | (4) | % | (20) | % | ||||||
Makeup | (5) | — | (5) | (9) | ||||||||||
Fragrance | 14 | (10) | (6) | (2) | ||||||||||
Hair Care | 7 | — | (4) | 4 | ||||||||||
Other | (3) | 7 | (7) | (3) | ||||||||||
Subtotal | (8) | % | (1) | % | (5) | % | (14) | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | (8) | % | (1) | % | (5) | % | (14) | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (the license terminations related to certain of the Company’s designer fragrances); as well as the impact of foreign currency translation. | ||||||||||||||
(2)Percentages are calculated on an individual basis |
Page 17 of 22 |
Results by Geographic Region (Unaudited) | |||||||||||||||||||||||
Six Months Ended December 31 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income (Loss) | Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
The Americas | $ | 2,358 | $ | 2,494 | (5) | % | (6) | % | $ | 40 | $ | 636 | (94) | % | |||||||||
Europe, the Middle East & Africa | 3,498 | 4,211 | (17) | (13) | 743 | 1,085 | (32) | ||||||||||||||||
Asia/Pacific | 2,700 | 3,228 | (16) | (7) | 449 | 653 | (31) | ||||||||||||||||
Subtotal | $ | 8,556 | $ | 9,933 | (14) | % | (9) | % | $ | 1,232 | $ | 2,374 | (48) | % | |||||||||
Returns/charges associated with restructuring and other activities | (6) | (2) | (15) | (21) | |||||||||||||||||||
Total | $ | 8,550 | $ | 9,931 | (14) | % | (9) | % | $ | 1,217 | $ | 2,353 | (48) | % |
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Six Months Ended December 31 2022 vs. 2021(2) | ||||||||||||||
Organic Net Sales Growth (Non-GAAP)(1) | Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) | |||||||||||
The Americas | (3) | % | (3) | % | 1 | % | (5) | % | ||||||
Europe, the Middle East & Africa | (12) | (1) | (4) | (17) | ||||||||||
Asia/Pacific | (7) | — | (9) | (16) | ||||||||||
Subtotal | (8) | % | (1) | % | (5) | % | (14) | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | (8) | % | (1) | % | (5) | % | (14) | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (the license terminations related to certain of the Company’s designer fragrances); as well as the impact of foreign currency translation. | ||||||||||||||
(2)Percentages are calculated on an individual basis |
Page 18 of 22 |
Page 19 of 22 |
Reconciliation of Certain Consolidated Statements of Earnings Accounts Before and After Returns, Charges and Other Adjustments (Unaudited) | ||||||||||||||||||||||||||||||||
Three Months Ended December 31 | ||||||||||||||||||||||||||||||||
2022 | 2021 | % Change | ||||||||||||||||||||||||||||||
($ in millions, except per share data) | As Reported | Returns/ Charges/ Adjustments | Non-GAAP | Impact of Foreign Currency Translation | Non-GAAP, Constant Currency | As Reported | Returns/ Charges/ Adjustments | Non-GAAP | Non-GAAP | Non-GAAP, Constant Currency | ||||||||||||||||||||||
Net sales | $ | 4,620 | $ | 1 | $ | 4,621 | $ | 282 | $ | 4,903 | $ | 5,539 | $ | 1 | $ | 5,540 | (17) | % | (11) | % | ||||||||||||
Cost of sales | 1,219 | — | 1,219 | 64 | 1,283 | 1,223 | (1) | 1,222 | ||||||||||||||||||||||||
Gross profit | 3,401 | 1 | 3,402 | 218 | 3,620 | 4,316 | 2 | 4,318 | (21) | % | (16) | % | ||||||||||||||||||||
Gross margin | 73.6 | % | 73.6 | % | 73.8 | % | 77.9 | % | 77.9 | % | ||||||||||||||||||||||
Operating expenses | 2,845 | (211) | 2,634 | 150 | 2,784 | 2,898 | (15) | 2,883 | (9) | % | (3) | % | ||||||||||||||||||||
Operating expense margin | 61.6 | % | 57.0 | % | 56.8 | % | 52.3 | % | 52.0 | % | ||||||||||||||||||||||
Operating income | 556 | 212 | 768 | 68 | 836 | 1,418 | 17 | 1,435 | (46) | % | (42) | % | ||||||||||||||||||||
Operating income margin | 12.0 | % | 16.6 | % | 17.1 | % | 25.6 | % | 25.9 | % | ||||||||||||||||||||||
Provision for income taxes | 135 | 50 | 185 | 17 | 202 | 298 | 3 | 301 | (39) | % | (33) | % | ||||||||||||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. | $ | 394 | $ | 162 | $ | 556 | $ | 54 | $ | 610 | $ | 1,088 | $ | 14 | $ | 1,102 | (50) | % | (45) | % | ||||||||||||
Diluted EPS | $ | 1.09 | $ | .45 | $ | 1.54 | $ | .15 | $ | 1.69 | $ | 2.97 | $ | .04 | $ | 3.01 | (49) | % | (44) | % | ||||||||||||
Six Months Ended December 31 | ||||||||||||||||||||||||||||||||
2022 | 2021 | % Change | ||||||||||||||||||||||||||||||
($ in millions, except per share data) | As Reported | Returns/ Charges/ Adjustments | Non-GAAP | Impact of Foreign Currency Translation | Non-GAAP, Constant Currency | As Reported | Returns/ Charges/ Adjustments | Non-GAAP | Non-GAAP | Non-GAAP, Constant Currency | ||||||||||||||||||||||
Net sales | $ | 8,550 | $ | 6 | $ | 8,556 | $ | 458 | $ | 9,014 | $ | 9,931 | $ | 2 | $ | 9,933 | (14) | % | (9) | % | ||||||||||||
Cost of sales | 2,242 | 1 | 2,243 | 94 | 2,337 | 2,280 | — | 2,280 | ||||||||||||||||||||||||
Gross profit | 6,308 | 5 | 6,313 | 364 | 6,677 | 7,651 | 2 | 7,653 | (18) | % | (13) | % | ||||||||||||||||||||
Gross margin | 73.8 | % | 73.8 | % | 74.1 | % | 77.0 | % | 77.0 | % | ||||||||||||||||||||||
Operating expenses | 5,091 | (214) | 4,877 | 265 | 5,142 | 5,298 | (21) | 5,277 | (8) | % | (3) | % | ||||||||||||||||||||
Operating expense margin | 59.5 | % | 57.0 | % | 57.0 | % | 53.3 | % | 53.1 | % | ||||||||||||||||||||||
Operating income | 1,217 | 219 | 1,436 | 99 | 1,535 | 2,353 | 23 | 2,376 | (40) | % | (35) | % | ||||||||||||||||||||
Operating income margin | 14.2 | % | 16.8 | % | 17.0 | % | 23.7 | % | 23.9 | % | ||||||||||||||||||||||
Other income | — | — | — | — | — | 1 | (1) | — | ||||||||||||||||||||||||
Provision for income taxes | 278 | 52 | 330 | 24 | 354 | 500 | 4 | 504 | (35) | % | (30) | % | ||||||||||||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. | $ | 883 | $ | 167 | $ | 1,050 | $ | 78 | $ | 1,128 | $ | 1,780 | $ | 18 | $ | 1,798 | (42) | % | (37) | % | ||||||||||||
Diluted EPS | $ | 2.45 | $ | .46 | $ | 2.91 | $ | .22 | $ | 3.13 | $ | 4.85 | $ | .05 | $ | 4.90 | (41) | % | (36) | % | ||||||||||||
Page 20 of 22 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, except where noted) | |||||||||||
December 31, 2022 | June 30, 2022 | December 31, 2021 | |||||||||
($ in millions) | (Audited) | ||||||||||
ASSETS | |||||||||||
Cash and cash equivalents | $ | 3,725 | $ | 3,957 | $ | 4,603 | |||||
Accounts receivable, net | 1,932 | 1,629 | 2,079 | ||||||||
Inventory and promotional merchandise | 3,069 | 2,920 | 2,612 | ||||||||
Prepaid expenses and other current assets | 641 | 792 | 661 | ||||||||
Total current assets | 9,367 | 9,298 | 9,955 | ||||||||
Property, plant and equipment, net | 2,908 | 2,650 | 2,451 | ||||||||
Operating lease right-of-use assets | 1,847 | 1,949 | 2,102 | ||||||||
Other assets | 6,609 | 7,013 | 7,570 | ||||||||
Total assets | $ | 20,731 | $ | 20,910 | $ | 22,078 | |||||
LIABILITIES AND EQUITY | |||||||||||
Current debt | $ | 260 | $ | 268 | $ | 272 | |||||
Accounts payable | 1,507 | 1,822 | 1,639 | ||||||||
Operating lease liabilities | 349 | 365 | 397 | ||||||||
Other accrued liabilities | 3,539 | 3,360 | 3,454 | ||||||||
Total current liabilities | 5,655 | 5,815 | 5,762 | ||||||||
Long-term debt | 5,111 | 5,144 | 5,259 | ||||||||
Long-term operating lease liabilities | 1,757 | 1,868 | 2,028 | ||||||||
Other noncurrent liabilities | 1,487 | 1,651 | 1,937 | ||||||||
Total noncurrent liabilities | 8,355 | 8,663 | 9,224 | ||||||||
Redeemable noncontrolling interest | 819 | 842 | 840 | ||||||||
Total equity | 5,902 | 5,590 | 6,252 | ||||||||
Total liabilities and equity | $ | 20,731 | $ | 20,910 | $ | 22,078 | |||||
Page 21 of 22 |
SELECT CASH FLOW DATA (Unaudited) | ||||||||
Six Months Ended December 31 | ||||||||
($ in millions) | 2022 | 2021 | ||||||
Net earnings | $ | 887 | $ | 1,785 | ||||
Adjustments to reconcile net earnings to net cash flows from operating activities: | ||||||||
Depreciation and amortization | 359 | 364 | ||||||
Deferred income taxes | (31) | (43) | ||||||
Impairment of other intangible assets | 207 | — | ||||||
Other items | 192 | 212 | ||||||
Changes in operating assets and liabilities: | ||||||||
Increase in accounts receivable, net | (295) | (407) | ||||||
Increase in inventory and promotional merchandise | (156) | (164) | ||||||
Decrease (increase) in other assets, net | 33 | (57) | ||||||
Increase (decrease) in accounts payable and other liabilities, net | (445) | 156 | ||||||
Net cash flows provided by operating activities | $ | 751 | $ | 1,846 | ||||
Other Investing and Financing Sources (Uses): | ||||||||
Capital expenditures | $ | (419) | $ | (459) | ||||
Settlement of net investment hedges | 138 | 58 | ||||||
Payments to acquire treasury stock | (257) | (1,428) | ||||||
Dividends paid | (451) | (409) | ||||||
Proceeds (repayments) of current debt, net | 244 | (4) | ||||||
Repayments and redemptions of long-term debt, net | (258) | (10) |
Page 22 of 22 |